Trials / Completed
CompletedNCT06024642
Study of V117957 in Overactive Bladder Syndrome
Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Overactive Bladder Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Imbrium Therapeutics · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | V117957 | V117957 1 mg - 1 tablet taken orally at bedtime. |
| DRUG | Placebo | Placebo to match V117957 tablets - 1 tablet taken orally at bedtime. |
Timeline
- Start date
- 2022-06-30
- Primary completion
- 2024-05-21
- Completion
- 2024-05-21
- First posted
- 2023-09-06
- Last updated
- 2025-06-26
- Results posted
- 2025-06-26
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06024642. Inclusion in this directory is not an endorsement.